The incidence of spinal metastasis associated with NSCLC is increasing because of improved survival in these patients based on recent advancements in systemic treatment for NSCLC, such as tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) mutations [4,5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.